Regeneron reports Phase II data for evinacumab in HoFH
Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) reported data from an open-label, international Phase II trial in 9 patients with homozygous familial hypercholesterolemia (HoFH) showing that evinacumab (REGN1500) added to current lipid-lowering therapy reduced mean LDL-C from baseline to week 4, the primary endpoint, by 49%. Four patients achieved an LDL-C of <100 mg/dL. Additionally, evinacumab reduced median triglyceride levels by 47%, mean HDL-C by 36%, mean total cholesterol levels by 47%, median lipoprotein(a) (LPA) levels by 19% and mean apolipoprotein B (APOB) levels by 46% from baseline to week 4. Data were presented at the National Lipid Association meeting in Philadelphia...
BCIQ Company Profiles
BCIQ Target Profiles